Sobetirome
A thyroid-hormone-receptor β-selective agonist — technically a small-molecule diphenylmethane thyromimetic (328.4 Da), not a peptide — included in this atlas as an adjacent-literature reference because it comes up in peptide-metabolism, MASLD, and lipid-modulation discussions and is frequently confused with peptide-class drugs. Originally developed for dyslipidemia (Karo Bio, 1998); now pursued for CNS demyelinating disease via the brain-penetrant amide prodrug Sob-AM2.
Sobetirome, also called GC-1, is not a peptide at all — it is a small molecule of 328 daltons, and it is on this site mainly because gray-market catalogs keep filing it under peptides. It was designed in 1998 to capture the fat- and cholesterol-lowering effects of thyroid hormone while avoiding the heart and bone effects that make thyroid excess dangerous, and it worked well enough in a single Phase 1 trial to lower LDL by up to 41%. It then ran out of money in 2008 and never entered Phase 2. Its real legacy is as the template for an entire drug class, including resmetirom, the first approved MASH drug. Its second life is a brain-targeted version being explored for rare neurological disease. Nothing here is approved, and self-dosing thyroid-mimicking drugs is genuinely dangerous.
What is Sobetirome?
Sobetirome — originally designated GC-1 — is a small-molecule thyromimetic (a 328.4 Da diphenylmethane, formula C20H24O4, structurally unrelated to peptides) that selectively activates the thyroid hormone receptor β (TRβ) subtype with roughly 10-fold preference over TRα. It was designed in Thomas Scanlan and John Baxter's collaborative program at UCSF/OHSU and reported in Chiellini et al., Chemistry & Biology 1998, as one of the first genuinely subtype-selective thyroid hormone analogs. The TRβ selectivity was engineered specifically to capture the hepatic lipid-lowering effects of thyroid hormone (a TRβ-dominant tissue) while sparing the cardiac and skeletal-muscle TRα-mediated effects that make actual thyroid hormone excess dangerous. Sobetirome is included in this atlas as a reference entry — it is unambiguously not a peptide, but it appears often enough in metabolic-therapeutics conversations adjacent to GLP-1/GIP peptides, tesamorelin (visceral fat), and MASLD pharmacotherapy that a clarifying page is useful. The clinically relevant TRβ agonist to know about today is resmetirom (Rezdiffra), approved by the FDA on 14 March 2024 as the first therapy for MASH with fibrosis — a mechanistic descendant of the GC-1 template. That approval is still an accelerated approval as of the current label: it rests on improvement in MASH and fibrosis rather than on clinical outcomes, and continued approval depends on confirmatory trials. Sobetirome itself never got as far as most summaries suggest: it completed a single Phase 1 trial and was terminated in 2008 by QuatRx Pharmaceuticals for lack of funding, before any Phase 2 study was run. That is worth stating precisely, because the usual account — that it was stopped by the thyromimetic class safety problems — is chronologically impossible, since the eprotirome cartilage signal that soured the class did not emerge until 2012. It was subsequently repurposed at OHSU into a brain-penetrant amide prodrug — Sob-AM2 (also called sobetiramide) — designed to be hydrolyzed by fatty-acid amide hydrolase (FAAH) inside the brain to release active sobetirome selectively in the CNS. This CNS-selective prodrug approach is the basis for investigational programs in X-linked adrenoleukodystrophy (X-ALD), MCT8 deficiency (Allan-Herndon-Dudley syndrome), and multiple sclerosis remyelination. Autobahn Therapeutics carried a related next-generation thyromimetic (ABX-002) into clinical development. As of 2026 sobetirome and Sob-AM2 remain investigational; neither is approved for any indication.
What Sobetirome Is Investigated For
Sobetirome / GC-1 matters as a foundational scientific template, not as a therapeutic in current clinical use. The strongest legacy is mechanistic: Chiellini and colleagues' 1998 paper established that TRβ-selective agonism could dissociate the hepatic lipid-lowering effects of thyroid hormone from the cardiac/musculoskeletal TRα effects that limit thyroid-hormone excess as a therapy. Every subsequent TRβ-selective thyromimetic — resmetirom (Madrigal, approved for MASH 2024), VK2809 (Viking), eprotirome (KB2115, Phase 3 failure), ASC41 (Ascletis), and Autobahn Therapeutics' ABX-002 — traces its design logic to GC-1. Direct clinical development of sobetirome for hypercholesterolemia stopped after a single Phase 1 trial, terminated by QuatRx in 2008 for lack of funding rather than for any safety finding; the class-level cartilage and liver signals that ended enthusiasm for TRβ agonists in lipid-lowering came later, from eprotirome in 2012. The active current story is the OHSU program (Scanlan and colleagues) that reformulated sobetirome as Sob-AM2 — a CNS-selective amide prodrug hydrolyzed by fatty-acid amide hydrolase (FAAH) in brain tissue to release active drug preferentially in the CNS. Preclinical data in X-linked adrenoleukodystrophy (X-ALD), MCT8 deficiency, and MS demyelination has been substantial; human clinical translation is still early. This page exists as an atlas-adjacent reference because sobetirome comes up frequently in metabolic-peptide discussions (tesamorelin visceral fat, GLP-1-class MASLD effects) and because 'GC-1' is often incorrectly listed among peptide compounds in gray-market catalogs and biohacker forums — it is not a peptide, it is not sold as a legitimate consumer product anywhere, and self-administration of investigational thyromimetics carries genuinely serious cardiac and metabolic risks.
History & Discovery
Sobetirome originated in a UCSF-OHSU collaboration led by Thomas Scanlan (medicinal chemistry) and John Baxter (thyroid hormone endocrinology) in the mid-1990s, building on the idea that the two thyroid hormone receptor isoforms — TRα and TRβ — had different tissue distributions that might allow subtype-selective ligands to dissociate hepatic from cardiac thyroid-hormone effects. Grazia Chiellini, then a postdoctoral fellow with Scanlan, led the medicinal chemistry that produced GC-1. (Online sources often gloss the name as standing for something — Grazia Compound 1, or Chiellini's initials — but no published source supports any of these, so this page does not repeat them.) The compound was reported in Chiellini et al., Chemistry & Biology, June 1998 — a paper that has since been widely cited as the foundational proof of concept for TRβ-selective drug design. QuatRx Pharmaceuticals, a Michigan company, took sobetirome through preclinical toxicology and into human Phase 1 pharmacology — the origin of the molecule's alternative designation QRX-431, which is a QuatRx code rather than a Karo Bio one. The Phase 1 study showed the expected LDL-lowering profile, reducing LDL cholesterol by up to 41% in normolipidaemic subjects over two weeks, without the cardiac stimulation that limits thyroid hormone itself. No Phase 2 study ever followed: QuatRx terminated the programme in 2008 for lack of funding. Separately, the Swedish nuclear-receptor company Karo Bio developed a different TRβ agonist — eprotirome (KB2115) — that reached a Phase 3 lipid-lowering trial called the AKKA study in the early 2010s. Karo Bio and eprotirome are frequently and wrongly merged into sobetirome's story; they are a different company and a different molecule. The AKKA study was terminated in 2012 after dog toxicology data showed cartilage damage at exposures being evaluated in humans, and the trial publication reported its own liver signal as well — significant elevations in AST, ALT, conjugated bilirubin and GGT, with four patients discontinuing for transaminase rises, leading the authors to conclude that eprotirome had the potential to induce liver injury. That combination, plus the parallel commercial success of statins and PCSK9 inhibitors in the same therapeutic space, effectively ended enthusiasm for TRβ agonists in lipid-lowering. Sobetirome had already been shelved four years earlier, so the class collapse is the reason nobody picked it back up rather than the reason it stopped. A parallel academic reinterpretation of the molecule then reshaped its trajectory. At Oregon Health & Science University (OHSU), Scanlan and colleagues (including Skyler Jenkins, Meredith Hartley, and others) developed Sob-AM2 — the amide prodrug of sobetirome that is hydrolyzed by fatty-acid amide hydrolase (FAAH) in brain tissue to release active drug preferentially in the CNS. Meinig et al. 2017 in ACS Chemical Neuroscience established the FAAH-prodrug strategy, and subsequent papers extended the approach to X-linked adrenoleukodystrophy (X-ALD, where the therapeutic goal is inducing ABCD2 to compensate for defective ABCD1) and MCT8 deficiency / Allan-Herndon-Dudley syndrome (where the goal is bypassing the defective brain thyroid hormone transporter). Autobahn Therapeutics (San Diego), founded in 2018 with connections to the OHSU program, has advanced ABX-002 — a related next-generation thyromimetic — into clinical development. The broader TRβ-selective thyromimetic class continued to mature independently: resmetirom (Madrigal Pharmaceuticals) received FDA approval in March 2024 as Rezdiffra for MASH with fibrosis — the first regulatory success in the entire class, and a direct descendant of the GC-1 template three decades after Chiellini's original paper.
How It Works
Thyroid hormone (T3) makes the liver burn fat and lower LDL cholesterol — but it also speeds up the heart, weakens bones, and shrinks muscle at doses high enough to matter for fat loss. Sobetirome is a small molecule designed to hit only the specific thyroid receptor (TRβ) that lives in the liver, while mostly ignoring the receptor (TRα) that drives the heart and bone effects. In theory this gives you the metabolic upside of thyroid hormone without the classic dangers of taking too much of it. In practice, the thyromimetic drug class has repeatedly hit safety walls in late-stage trials, and sobetirome itself never crossed the finish line for its original lipid-lowering indication. Its second life is as a brain-penetrant prodrug (Sob-AM2) for rare CNS diseases where restoring thyroid-hormone signaling inside the brain — without flooding the rest of the body — is the therapeutic goal.
Sobetirome (GC-1, 3,5-dimethyl-4-(4′-hydroxy-3′-isopropylbenzyl)-phenoxyacetic acid) is a diphenylmethane thyromimetic that binds thyroid hormone receptor β (TRβ) with substantially higher affinity than TRα, which was the design rationale. Published selectivity estimates vary — figures from roughly 3-fold to 18-fold appear in the literature, and Chiellini’s own later review describes GC-1 as binding TRβ with about the same affinity as T3 while binding TRα1 roughly 10-fold more weakly — so this page quotes the range rather than a single precise ratio. TR receptors are nuclear receptors that heterodimerize with retinoid X receptor (RXR) and bind thyroid hormone response elements (TREs) in the promoters of target genes, driving transcription of the standard thyroid-hormone-responsive gene set (SHBG, cholesterol-7-α-hydroxylase, low-density lipoprotein receptor upregulation, sterol regulatory element-binding protein 2, mitochondrial biogenesis pathways). TRβ is the dominant TR isoform in liver, pituitary, and hypothalamus; TRα predominates in cardiac muscle, skeletal muscle, and bone. This differential distribution is the mechanistic basis for TRβ-selective drug design: activating TRβ selectively should engage the hepatic lipid-lowering program (LDL reduction, hepatic triglyceride mobilization, cholesterol-to-bile-acid conversion) while sparing the cardiac and skeletal effects that make thyrotoxicosis dangerous. In practice, sobetirome lowered LDL cholesterol by up to 41% in normolipidaemic subjects after two weeks in its single Phase 1 study, without the increases in heart rate that would signal thyrotoxicosis. Development stopped for lack of funding in 2008 rather than for any sobetirome-specific safety failure. The subsequent successful thyromimetic (resmetirom) added additional selectivity refinements and a MASH-focused indication where hepatic thyroid-hormone signaling is more central than in general dyslipidemia. The Sob-AM2 prodrug is the amide (as opposed to the parent acid) of sobetirome. Amide prodrugs have improved blood-brain barrier permeability due to reduced polarity, and they are activated to the parent acid by fatty-acid amide hydrolase (FAAH), an enzyme with substantially higher activity in CNS than in peripheral tissues. This produces a CNS-selective exposure profile: measurable brain sobetirome concentrations from Sob-AM2 dosing with meaningfully lower peripheral exposure than would be achieved by giving the same amount of parent sobetirome. In X-ALD, the therapeutic hypothesis is that Sob-AM2 can activate brain TRβ enough to induce ABCD2 (a peroxisomal ABC transporter that partially compensates for the ABCD1 defect responsible for X-ALD) without producing peripheral thyromimetic side effects. In MCT8 deficiency, the hypothesis is that Sob-AM2 can bypass the defective MCT8 transporter (which normally moves T3 into brain tissue) by supplying TRβ activation via a different chemical route.
Evidence Snapshot
Human Clinical Evidence
Thin, and thinner than most summaries imply. Sobetirome has one completed Phase 1 trial and no Phase 2; its human lipid data reaches the literature only through secondary review reporting rather than a primary trial publication. No approved indication. For the CNS programme the honest statement is that no patient has yet been dosed in a registered trial: the two sobetirome studies on ClinicalTrials.gov were both withdrawn before enrolling anyone — the X-ALD study (NCT01787578) over protocol revisions, and NeuroVia’s pediatric NV1205 study (NCT03196765) for lack of funding in March 2019 — and no Sob-AM2 or sobetiramide trial has ever been registered at all. The TRβ agonist that has actually completed a trial in X-ALD patients is a different molecule, Viking’s VK0214 (NCT04973657, Phase 1b in adrenomyeloneuropathy, completed October 2024).
Animal / Preclinical
Extensive. Decades of rodent and non-human primate work characterize the TRβ selectivity, lipid-lowering effects, hepatic gene-expression signature, and CNS remyelination effects of sobetirome. Sob-AM2's CNS-selective pharmacokinetic advantage over parent sobetirome is well-documented in mouse studies.
Mechanistic Rationale
Very strong. TRβ vs TRα subtype distribution, nuclear receptor pharmacology, and the FAAH-mediated CNS activation of amide prodrugs are all well-characterized. Sobetirome was one of the field's foundational proofs-of-concept that receptor-subtype selectivity in nuclear-receptor pharmacology could dissociate desired from undesired hormone effects.
Research Gaps & Open Questions
What the current literature has not yet settled about Sobetirome:
- 01Whether Sob-AM2 delivers meaningful clinical benefit in X-linked adrenoleukodystrophy — the mechanistic case (ABCD2 induction via TRβ) is strong but human efficacy data is still forthcoming.
- 02Whether the CNS-selective delivery of Sob-AM2 is sufficient in patients with MCT8 deficiency (Allan-Herndon-Dudley syndrome) to correct the neurological phenotype — a rare-disease indication where the therapeutic window and long-term outcomes are still being defined.
- 03Long-term safety of chronic CNS-selective thyromimetic exposure — the FAAH-prodrug approach reduces peripheral exposure, but chronic CNS TRβ activation over years has not been characterized in humans.
- 04Whether next-generation thyromimetics (ABX-002, VK2809) that share the GC-1 design rationale but differ in specific selectivity and PK profiles produce meaningfully different safety-efficacy trade-offs than sobetirome — differences at the compound level rather than the class level.
- 05The cartilage-safety signal from the eprotirome Phase 3 termination — whether sobetirome and Sob-AM2 share this liability at clinically relevant exposures, or whether their specific selectivity profiles mitigate it.
- 06Whether MASLD/MASH indications, now dominated by resmetirom, could accommodate a sobetirome-derived agent — commercial and clinical rationale is limited given resmetirom's approved-first-in-class position, but a MASH-plus-lipid-lowering profile might differentiate.
- 07Whether the biohacker-market use of 'GC-1' for fat loss produces measurable harm at population scale — anecdotal reports of cardiac symptoms exist but no systematic surveillance data has been reported.
Forms & Administration
Sobetirome is not commercially available in any FDA-approved formulation. In academic and industry research, it has been administered orally (rodent studies and one clinical Phase 1 study) as sobetirome free acid or hydrochloride at doses ranging from micrograms/kg (mouse) to milligram-scale (human Phase 1). Sob-AM2 is administered orally in preclinical studies and in the early-phase clinical programs derived from the OHSU work. There is no approved dose, no legitimate outpatient pharmacy channel, and no wellness-appropriate formulation. Products sold as 'GC-1' or 'sobetirome' by research-chemical vendors are not verified for identity, purity, or sterility, and the biohacker use of thyromimetics for fat loss is not supported by any clinical evidence and carries documented cardiac and musculoskeletal risks. Any legitimate access is through enrollment in a sponsored clinical trial of Sob-AM2 or a next-generation thyromimetic.
Common Questions
Is Sobetirome (GC-1) actually a peptide?
No. Sobetirome is a diphenylmethane small-molecule thyromimetic with a molecular weight of 328.4 Da (C20H24O4, PubChem CID 9862248) — structurally unrelated to peptides. It contains no amino acid residues. It is included in this atlas as a reference entry because it appears often in peptide-adjacent metabolic and lipid-modulation discussions and because it is sometimes mis-listed as a peptide in gray-market catalogs. The correct classification is 'TRβ-selective thyromimetic small molecule.'
Why did sobetirome development for cholesterol stop?
Not for the reason most sources give. Sobetirome completed one Phase 1 trial, in which it lowered LDL cholesterol by up to 41% in normolipidaemic subjects after two weeks, and it never entered Phase 2 at all. QuatRx Pharmaceuticals terminated the programme in 2008 for lack of funding, and the reviews that describe its human experience record no adverse effects of the kind thyroid hormone excess produces. The class-wide safety story came later and is a separate thread. The emblematic event was the Phase 3 failure of eprotirome (KB2115), Karo Bio's follow-on TRβ agonist, which was halted in 2012 after cartilage damage was observed in dog toxicology at doses being tested in humans. That class-level signal, together with the liver injury AKKA itself found — significant rises in AST, ALT, conjugated bilirubin and GGT, with four patients discontinuing for transaminase elevations — effectively ended enthusiasm for TRβ agonists in lipid-lowering. It arrived four years after sobetirome had already been shelved, so it explains why nobody revived the molecule, not why it stopped. The class re-emerged a decade later with tighter selectivity and safer profiles — culminating in resmetirom's 2024 FDA approval for MASH — but sobetirome itself was not the molecule that made it across.
What is Sob-AM2 and how does it work?
Sob-AM2 (also called sobetiramide) is an amide prodrug of sobetirome designed at OHSU by Tom Scanlan and colleagues to deliver the active drug preferentially to the central nervous system. The prodrug crosses the blood-brain barrier better than sobetirome itself and is then hydrolyzed by fatty-acid amide hydrolase (FAAH) — an enzyme highly expressed in brain tissue — to release active sobetirome inside the CNS. Because FAAH activity is much higher in brain than in peripheral tissues, this creates a CNS-selective sobetirome exposure profile with reduced peripheral thyromimetic effects (which drive most of the class-level cardiac and cartilage concerns). Sob-AM2 is the platform behind the current X-ALD and MCT8-deficiency programs.
How does sobetirome relate to resmetirom, VK2809, and ABX-002?
All four are TRβ-selective thyromimetics designed to exploit hepatic thyroid hormone signaling while avoiding cardiac and skeletal effects. Sobetirome (1998) is the foundational template. Resmetirom (Madrigal Pharmaceuticals, FDA-approved March 2024 as Rezdiffra) is the first thyromimetic to reach approval, indicated for MASH with fibrosis — a mechanistic and structural descendant of GC-1. VK2809 (Viking Therapeutics) is often described as late-stage, but ClinicalTrials.gov lists only two VK2809 studies, both Phase 2 and both completed — a hypercholesterolemia and NAFLD trial finished in 2019 and the VOYAGE biopsy-proven NASH trial finished in May 2023. No Phase 3 has been registered, and no homozygous familial hypercholesterolemia trial of VK2809 exists in any phase. The HoFH idea traces instead to a 2012 Endocrinology paper showing that GC-1 and eprotirome lower cholesterol by an LDL-receptor-independent route via Cyp7a1, which its authors suggested might suit HoFH — a mechanistic hypothesis about GC-1, not a VK2809 programme. ABX-002 (Autobahn Therapeutics), which now carries the INN elunetirom, is a next-generation thyromimetic in clinical development — but not in metabolic disease. It is structurally the dichloro analogue of Sob-AM2, carrying the same N-methyl amide prodrug motif, and all four of its registered trials are in psychiatry: Phase 2 studies of adjunctive treatment in major depressive disorder and in bipolar depression, plus two completed Phase 1 studies. It is the clearest evidence that the CNS-selective thyromimetic idea has outgrown the lipid-lowering context in which sobetirome began. None of these is sobetirome — they are structurally and pharmacokinetically distinct molecules in the same drug class, and clinicians should not use sobetirome data to predict resmetirom outcomes or vice versa.
Can I buy Sobetirome or GC-1 as a research chemical?
Sobetirome and GC-1 are sold by some research-chemical suppliers, but none of these products are FDA-approved, sponsor-manufactured, or verified for identity, purity, or human safety. Sobetirome is an investigational drug that has never received regulatory approval. Self-administration of thyromimetics is genuinely risky: the class carries documented concerns about atrial arrhythmia, cardiac remodeling, cartilage damage (from the eprotirome program), thyrotoxicosis-like symptoms, and hypothalamic-pituitary-thyroid axis disruption. Sobetirome's TRβ selectivity is protective on paper but not sufficient at supratherapeutic doses. There is no legitimate wellness, longevity, or performance-enhancement use case, and the biohacker framing of 'GC-1 for fat loss' understates the risk profile and overstates the evidence.
Who Sobetirome Is NOT For
- •Pregnancy and breastfeeding — no adequate human safety data; thyromimetics cross the placenta and can disturb fetal thyroid axis development. Absolute avoidance outside investigational study protocols.
- •Cardiac disease including arrhythmia, ischemic heart disease, or heart failure — thyromimetic class carries documented atrial arrhythmia risk that scales with dose and duration.
- •Uncontrolled hyperthyroidism or subclinical hyperthyroidism — additive HPT-axis suppression compounds thyromimetic effects.
- •Known thyroid nodule or thyroid cancer history without endocrinology clearance.
- •Concurrent thyroid hormone replacement (levothyroxine, liothyronine) — additive effects and complex axis interactions.
- •Hepatic or renal impairment — pharmacokinetics not characterized in these populations.
- •History of cartilage or joint disease — the eprotirome cartilage safety signal is a class-level concern that has not been definitively excluded for sobetirome specifically.
- •Any self-administration outside a regulated clinical trial — investigational thyromimetic use has caused hospitalization, and unverified research-chemical product cannot be assumed to be authentic.
Drug & Supplement Interactions
Sobetirome has meaningful pharmacodynamic and pharmacokinetic interactions to consider even though most are theoretical given the absence of a licensed product. Thyroid hormone replacement (levothyroxine, liothyronine) will produce additive TR activation and additive HPT-axis suppression; concurrent use is not appropriate outside protocol-defined study conditions. Antithyroid agents (methimazole, propylthiouracil) counter thyroid hormone synthesis but do not block sobetirome's direct TRβ activation. Warfarin and other narrow-therapeutic-index anticoagulants can be sensitive to thyromimetic-driven changes in vitamin K-dependent clotting factor turnover; close INR monitoring would be required if sobetirome were used clinically. Statins, PCSK9 inhibitors, and bempedoic acid produce lipid-lowering effects that overlap with sobetirome's mechanism; in the historical clinical program, these were expected to be additive rather than synergistic. Beta-blockers may mask thyromimetic-driven tachycardia and are sometimes co-administered in thyroid-hormone-excess management. CNS-active drugs are of particular interest for Sob-AM2 development because FAAH is inhibited by the endocannabinoid-modulating drug class (FAAH inhibitors are in development for pain and psychiatric indications); concurrent FAAH inhibition would meaningfully reduce Sob-AM2's CNS activation. As a specialty investigational drug, any actual clinical use should have all concurrent medications disclosed to the study team.
Safety Profile
Common Side Effects
Cautions
- • Not FDA-approved for any indication as of 2026
- • Thyromimetic class carries documented cardiac (atrial arrhythmia), musculoskeletal (cartilage damage in dog toxicology of eprotirome), and HPT-axis (TSH suppression) safety concerns
- • Self-administered thyromimetics have caused hospitalization; treat any sobetirome or GC-1 offered outside a regulated clinical trial as a research chemical with unknown identity and purity
- • Concurrent thyroid disease, cardiac disease, or hypothalamic-pituitary abnormalities are contraindications for any thyromimetic exposure
- • The biohacker 'GC-1 for fat loss' framing understates the cardiac and cartilage risk and overstates the human evidence
What We Don't Know
Long-term (multi-year) safety of chronic thyromimetic exposure at doses producing measurable TRβ activation is not fully characterized for sobetirome specifically — the human data is limited to one short Phase 1 exposure. Whether Sob-AM2's CNS-selective delivery translates into an acceptable long-term safety margin in X-ALD and MCT8-deficiency patients is the central open question for the ongoing OHSU-derived clinical programs.
Legal Status
United States
Sobetirome is not FDA-approved for any indication. It is not a controlled substance. It is available as a research chemical from academic laboratories and some commercial suppliers, but there is no authorized human-use pathway outside of sponsored clinical trials (currently for Sob-AM2 and next-generation thyromimetic analogs). Products marketed as 'GC-1' or 'sobetirome' through supplement or peptide retail channels are not FDA-authorized and cannot be assumed to be authentic or safe.
International
No regulator has approved sobetirome for human therapeutic use. Karo Bio's earlier programs were pursued through EMA and other jurisdictions but did not result in approval. Sob-AM2 and next-generation thyromimetic analogs are being developed under investigational-drug frameworks appropriate to each jurisdiction.
Sports & Competition
Sobetirome is not named on the WADA Prohibited List (2026, or the 2027 List in force from 1 January 2027), and the List does not name thyroid hormones or thyromimetics; S4 (hormone and metabolic modulators) covers aromatase inhibitors, anti-estrogens, agents preventing activin receptor IIB activation, and named metabolic modulators, not thyroid-receptor agonists. Because sobetirome has no approval from any government health authority, it falls under S0 (non-approved substances), which is prohibited at all times, in and out of competition.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Sobetirome (GC-1) is a peptide.
Reality
It is not. Sobetirome is a diphenylmethane small molecule of 328.4 Da with no amino acid content. The mis-listing of GC-1 among peptides in some biohacker catalogs and gray-market suppliers is an error of classification, and it matters because peptide-focused regulatory discussions (FDA's 503A peptide decisions, WADA S2 for peptide hormones) do not describe its status: as an unapproved small molecule, it falls under general FDA drug law and WADA's S0 non-approved-substances section. Sobetirome is a small-molecule investigational thyromimetic.
Myth
Sobetirome is FDA-approved as a fat-loss drug.
Reality
It is not FDA-approved for any indication. Sobetirome development for hypercholesterolemia was paused when the broader thyromimetic class ran into safety concerns (particularly the eprotirome Phase 3 cartilage-damage signal). The only FDA-approved TRβ agonist as of 2026 is resmetirom (Rezdiffra), approved March 2024 for MASH with fibrosis — a related but structurally distinct molecule from sobetirome. Products advertised online as 'GC-1 for fat loss' are unregulated research chemicals, not approved pharmaceuticals.
Myth
Because sobetirome is TRβ-selective, it has no cardiac or musculoskeletal side effects.
Reality
TRβ selectivity reduces but does not eliminate the class-level cardiac and cartilage concerns. TRα is dominant but not exclusive in cardiac tissue, and supratherapeutic doses of any TRβ-selective agent can spill into TRα activation. Additionally, dose-dependent adverse effects (atrial arrhythmia, bone-turnover changes, cartilage damage in animal models) have been observed across the thyromimetic class regardless of the specific TRβ selectivity ratio. The 'selective means safe' framing is a marketing simplification.
Myth
GC-1 works the same way as tesamorelin or GLP-1 agonists for fat loss.
Reality
It does not. GC-1 is a nuclear-receptor agonist that activates hepatic thyroid-hormone signaling — it lowers LDL, mobilizes hepatic triglycerides, and (at doses that produce systemic effects) alters basal metabolic rate. Tesamorelin is a GHRH analog that promotes visceral fat loss via GH/IGF-1 signaling; GLP-1 receptor agonists suppress appetite and slow gastric emptying to reduce caloric intake. The three drug classes have completely different mechanisms, side effect profiles, and evidence bases. Combining them empirically outside clinical study protocols is not supported by evidence.
Myth
Sob-AM2 is the same drug as sobetirome, just repackaged.
Reality
Sob-AM2 is a distinct chemical entity — the amide prodrug of sobetirome — designed for CNS-selective delivery via FAAH activation. It has different pharmacokinetics, different biodistribution, and different indications (rare CNS demyelinating diseases rather than lipid lowering). The two should not be treated as interchangeable, and clinical data for one does not extrapolate to the other. Sob-AM2 remains investigational.
Published Research
18 studiesCentral Thyroid Hormone Receptor-Beta Agonist Selectively Inhibits Voluntary Alcohol Consumption in Mice
Thyroid hormones induce an acute platelet release mechanism via integrin αVβ3
Thyroid Hormone Analogs: Recent Developments
2025 Thyroid review covering the modern thyromimetic drug class — sobetirome, resmetirom (approved 2024), VK2809, ABX-002, and CNS-selective sobetirome prodrugs. The current-state single-reference update to the field.
Maternal Administration of the CNS-Selective Sobetirome Prodrug Sob-AM2 Exerts Thyromimetic Effects in Murine MCT8-Deficient Fetuses
Selective Thyroid Hormone Receptor-Beta (TRβ) Agonists: New Perspectives for the Treatment of Metabolic and Neurodegenerative Disorders
The Thyromimetic Sobetirome (GC-1) Alters Bile Acid Metabolism in a Mouse Model of Hepatic Cholestasis
Pharmacological Complementation Remedies an Inborn Error of Lipid Metabolism
Myelin repair stimulated by CNS-selective thyroid hormone action
Hartley, Scanlan and colleagues 2019 JCI Insight — the paper the remyelination claim actually rests on, and one this page previously asserted without citing. It showed sobetirome and Sob-AM2 stimulate remyelination in gliotoxin models of demyelination, and, notably, that thyroid hormone itself did not reproduce the benefit, which is the clearest argument that TRβ-selective CNS delivery is doing something the parent hormone cannot.
Hypothalamic-Pituitary-Thyroid Axis Perturbations in Male Mice by CNS-Penetrating Thyromimetics
Sobetirome and its Amide Prodrug Sob-AM2 Exert Thyromimetic Actions in Mct8-Deficient Brain
Targeting Fatty-Acid Amide Hydrolase with Prodrugs for CNS-Selective Therapy
Meinig et al. 2017 ACS Chemical Neuroscience — the paper defining the FAAH-activated amide-prodrug strategy that produced Sob-AM2. Established the CNS-selective sobetirome delivery mechanism that anchors the current X-ALD and MCT8-deficiency programs.
GC-1: A Thyromimetic With Multiple Therapeutic Applications in Liver Disease
Sobetirome: the past, present and questions about the future
Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study
Sobetirome: a selective thyromimetic for the treatment of dyslipidemia
Sobetirome: a case history of bench-to-clinic drug discovery and development
Scanlan 2010 Heart Failure Reviews — first-person case history of sobetirome development by its principal designer. The canonical single-reference overview of GC-1's origin and early clinical experience.
Structural determinants of selective thyromimetics
Yoshihara, Apriletti, Baxter and Scanlan 2003 J Med Chem — structural basis of TRβ selectivity in the GC-1 scaffold. The medicinal-chemistry paper that anchored the class's design work.
A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor
Chiellini, Apriletti, Yoshihara, Baxter, Ribeiro, Scanlan 1998 Chemistry & Biology — the paper that reported GC-1 as one of the first genuinely subtype-selective thyroid hormone receptor agonists (~10-fold TRβ over TRα). Established the drug-design rationale that underlies every subsequent TRβ-selective thyromimetic including resmetirom, VK2809, eprotirome, and ABX-002.
Quick Facts
- Class
- Thyromimetic Small Molecule (Not a Peptide)
- Tier
- D
- Evidence
- Emerging
- Safety
- Limited Data
- Updated
- Nov 2026
- Citations
- 18PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.